856676-23-8,MFCD18382233
Catalog No.:AA004TDP

856676-23-8 | Choline Fenofibrate

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1g
98%
in stock  
$70.00   $49.00
- +
5g
98%
in stock  
$194.00   $136.00
- +
10g
98%
in stock  
$289.00 $203.00
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA004TDP
Chemical Name:
Choline Fenofibrate
CAS Number:
856676-23-8
Molecular Formula:
C22H28ClNO5
Molecular Weight:
421.9144
MDL Number:
MFCD18382233
SMILES:
Clc1ccc(cc1)C(=O)c1ccc(cc1)OC(C(=O)[O-])(C)C.OCC[N+](C)(C)C
Properties
Properties
 
BP:
486.5°C at 760 mmHg  
Form:
Solid  
MP:
206-212°C  
Storage:
Inert atmosphere;Room Temperature;  

Computed Properties
 
Complexity:
446  
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
29  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0  
Rotatable Bond Count:
6  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  

Literature

Title: ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.

Journal: Journal of clinical pharmacology 20090101

Title: Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

Journal: American heart journal 20090101

Title: Treatment of hyperlipidaemia with fenofibrate and related fibrates.

Journal: Expert opinion on investigational drugs 20081001

Title: Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

Journal: Clinical drug investigation 20080101

Title: Xudan Wei, et al. Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2017 Apr;31(4).

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:856676-23-8 Molecular Formula|856676-23-8 MDL|856676-23-8 SMILES|856676-23-8 Choline Fenofibrate
Catalog No.: AA004TDP
856676-23-8,MFCD18382233
856676-23-8 | Choline Fenofibrate
Pack Size: 1g
Purity: 98%
in stock
$70.00 $49.00
Pack Size: 5g
Purity: 98%
in stock
$194.00 $136.00
Pack Size: 10g
Purity: 98%
in stock
$289.00 $203.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA004TDP
Chemical Name: Choline Fenofibrate
CAS Number: 856676-23-8
Molecular Formula: C22H28ClNO5
Molecular Weight: 421.9144
MDL Number: MFCD18382233
SMILES: Clc1ccc(cc1)C(=O)c1ccc(cc1)OC(C(=O)[O-])(C)C.OCC[N+](C)(C)C
Properties
BP: 486.5°C at 760 mmHg  
Form: Solid  
MP: 206-212°C  
Storage: Inert atmosphere;Room Temperature;  
Complexity: 446  
Covalently-Bonded Unit Count: 2  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 29  
Hydrogen Bond Acceptor Count: 5  
Hydrogen Bond Donor Count: 1  
Isotope Atom Count: 0  
Rotatable Bond Count: 6  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
Literature fold

Title: ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.

Journal: Journal of clinical pharmacology20090101

Title: Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

Journal: American heart journal20090101

Title: Treatment of hyperlipidaemia with fenofibrate and related fibrates.

Journal: Expert opinion on investigational drugs20081001

Title: Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

Journal: Clinical drug investigation20080101

Title: Xudan Wei, et al. Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2017 Apr;31(4).

Building Blocks More >
85386-84-1
85386-84-1
1-(3-Fluoropyridin-2-yl)piperazine
AA004TYT | MFCD09910293
860363-17-3
860363-17-3
1H-Pyrrolo[3,2-b]pyridine-3-carboxylic acid hydrochloride
AA004UYJ | MFCD23135791
848819-82-9
848819-82-9
Methyl 4-(cyclopropylamino)-3-nitrobenzoate
AA004W6O | MFCD08448276
847956-14-3
847956-14-3
2-Thiazolecarboxylic acid, 4-(2-thienyl)-
AA004XCS | MFCD07377494
84211-05-2
84211-05-2
Mafosfamide Sodium Salt
AA004YFC | MFCD28899125
841295-69-0
841295-69-0
Methyl 4-(4-bromophenyl)piperazine-1-carboxylate
AA004ZGB | MFCD16036098
840479-48-3
840479-48-3
2-[(6-Chloro-4-ethyl-2-oxo-2h-chromen-7-yl)oxy]propanoic acid
AA0050I4 | MFCD03848270
78710-36-8
78710-36-8
Acetamide,2-chloro-N-[(2-methylphenyl)methyl]-
AA0051TE | MFCD08444138
813-78-5
813-78-5
Dimethyl phosphate
AA0052N2 | MFCD00014887
773873-72-6
773873-72-6
Methyl 3,4,5-trifluorobenzenecarboxylate
AA0053Q4 | MFCD06200977
Submit
© 2017 AA BLOCKS, INC. All rights reserved.